



Contact:

Stuart A. Arbuckle

Executive Vice President and Chief Operating Officer he/him/his

Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, MA 02210 +1 (617) 341-6100 vrtx.com

Joined Vertex: 2012

Education:

University of Leeds, UK

Stuart A. Arbuckle

Executive Vice President and Chief Operating Officer

Stuart A. Arbuckle joined Vertex in September 2012. As Vertex's Executive Vice President and Chief Operating Officer, Mr. Arbuckle oversees Vertex's global commercial team, which includes activities that support the approved use of Vertex's marketed medicines around the world. He also leads the program and portfolio management, human resources and corporate communications functions.

Mr. Arbuckle has more than 30 years of experience in leading global sales and marketing efforts at biopharmaceutical companies. Prior to joining Vertex, Mr. Arbuckle held multiple commercial leadership roles at Amgen, Inc. As Vice President and General Manager, Oncology Business Unit, he led sales, marketing, patient advocacy and access efforts for Amgen's portfolio of cancer medicines. He was responsible for sales and marketing efforts for Aranesp® (darbepoetin alfa), Neulasta® (pegfilgrastim) injection and NEUPOGEN® (filgrastim), which accounted for more than \$5 billion in sales in 2011, and led the successful launches of XGEVA® (denosumab) injection and Nplate® (romiplostim) injection. Most recently, he served as Vice President and Regional General Manager where he led efforts to expand Amgen's presence in Japan, Asia, the Middle East and Africa.

Prior to these roles, Mr. Arbuckle spent 15 years at GlaxoSmithKline (GSK) plc, where he held sales and marketing roles of increasing responsibility for medicines aimed at treating respiratory, metabolic, musculoskeletal, cardiovascular and other diseases. He joined GSK after earning a degree in pharmacology and physiology from the University of Leeds in the United Kingdom.

Mr. Arbuckle serves on the board of directors for Rhythm Pharmaceuticals and on the Executive Committee and Health Section Governing Board for the Biotechnology Innovation Organization (BIO). He is also co-chair of the BIO Standing Committee on Access & Value.